Article
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Oncology - 1 Jan 2011
Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger M M, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E
Abstract excerpt
BACKGROUND: Genetic alterations within the epidermal growth factor receptor (EGFR) pathway, including KRAS mutations, have been demonstrated to be associated with response to EGFR inhibitors like cetuximab in colorectal cancers. Mutations in the KRAS gene have been found in 70-90% of pancreatic cancers. Unfortunately, the addition of cetuximab to chemotherapy did not increase response or survival in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.